|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.405 SEK | +3.69% |
|
+3.69% | -64.83% |
| 05-15 | Transcript : Scandion Oncology A/S - Special Call | |
| 03-21 | Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival | CI |
Scandion Oncology A/S reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was DKK 9.29 million compared to DKK 12.92 million a year ago. Basic loss per share from continuing operations was DKK 0.23 compared to DKK 0.4 a year ago.
Diluted loss per share from continuing operations was DKK 0.23 compared to DKK 0.4 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.83% | 5.15M | |
| +9.58% | 114B | |
| +11.56% | 104B | |
| -14.01% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.00% | 17.89B | |
| +7.64% | 14.28B | |
| +36.07% | 12.55B |
SCANDION ONCOLOGY A/S 
